.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Dow
Citi
Cipla
Boehringer Ingelheim
Argus Health
McKesson
Chinese Patent Office
UBS
McKinsey

Generated: December 17, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,044,046

« Back to Dashboard

Claims for Patent: 8,044,046

Title:Medicaments for the treatment of chronic obstructive pulmonary disease
Abstract: A pharmaceutical composition comprising a compound of formula 1 ##STR00001## wherein: n is 1 or 2; R.sup.1 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.2 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.3 is hydrogen, C.sub.1-C.sub.4-alkyl, OH, halogen, --O--C.sub.1-C.sub.4-alkyl, --O--C.sub.1-C.sub.4-alkylene-COOH, or --O--C.sub.1-C.sub.4-alkylene-CO--O--C.sub.1-C.sub.4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
Inventor(s): Konetzki; Ingo (Warthausen, DE), Schromm; Kurt (Ingelheim am Rhein, DE), Schollenberger; Hermann (Ingelheim am Rhein, DE), Pestel; Sabine (Attenweiler, DE), Schnapp; Andreas (Biberach, DE), Bouyssou; Thierry (Warthausen, DE), Buettner; Frank (Attenweiler, DE), Heine; Claudia (Biberach, DE), Lustenberger; Philipp (Basel, CH), Hoenke; Christoph (Ingelheim, DE), Rudolf; Klaus (Warthausen, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co KG (Ingelheim, DE)
Application Number:11/132,075
Patent Claims: 1. A method for the treatment of Chronic Obstructive Pulmonary Disease (COPD) comprising administration of a therapeutically effective amount of R-6-Hydroxy-8-{1-hydroxy-2[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-- ethyl}-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof with a pharmacologically acceptable acid; and a pharmaceutically acceptable excipient or carrier.

2. A method for the treatment of Chronic Obstructive Pulmonary Disease (COPD) comprising administration of a therapeutically effective amount of R-8-{2-[2-(2,4-difluorophenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-- 6-hydroxy-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof with a pharmacologically acceptable acid; and a pharmaceutically acceptable excipient or carrier.

3. A method for the treatment of Chronic Obstructive Pulmonary Disease (COPD) comprising administration of a therapeutically effective amount of R-8-{2-[2-(3,5-difluorophenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-- 6-hydroxy-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof with a pharmacologically acceptable acid; and a pharmaceutically acceptable excipient or carrier.

4. A method for the treatment of Chronic Obstructive Pulmonary Disease (COPD) comprising administration of a therapeutically effective amount of R-8-{2-[2-(4-Ethoxy-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-h- ydroxy-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof with a pharmacologically acceptable acid; and a pharmaceutically acceptable excipient or carrier.

5. A method for the treatment of Chronic Obstructive Pulmonary Disease (COPD) comprising administration of a therapeutically effective amount of R-8-{2-[2-(4-fluorophenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hy- droxy-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof with a pharmacologically acceptable acid; and a pharmaceutically acceptable excipient or carrier.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
US Army
Colorcon
Boehringer Ingelheim
Citi
US Department of Justice
Novartis
AstraZeneca
Federal Trade Commission
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot